Bobbi J Woolwine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/918815/publications.pdf

Version: 2024-02-01

147801 330143 5,456 37 31 37 citations h-index g-index papers 39 39 39 5788 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression. JAMA Psychiatry, 2013, 70, 31.	11.0	1,314
2	CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression. Molecular Psychiatry, 2010, 15, 393-403.	7.9	546
3	Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression. Biological Psychiatry, 2009, 65, 296-303.	1.3	315
4	Dopaminergic Mechanisms of Reduced Basal Ganglia Responses to Hedonic Reward During Interferon Alfa Administration. Archives of General Psychiatry, 2012, 69, 1044.	12.3	306
5	Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy. Journal of Clinical Psychiatry, 2005, 66, 41-48.	2.2	262
6	What does plasma CRP tell us about peripheral and central inflammation in depression?. Molecular Psychiatry, 2020, 25, 1301-1311.	7.9	251
7	Anterior Cingulate Activation and Error Processing During Interferon-Alpha Treatment. Biological Psychiatry, 2005, 58, 190-196.	1.3	204
8	Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy. Neuropsychopharmacology, 2007, 32, 2384-2392.	5.4	203
9	Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology, 2018, 95, 43-49.	2.7	186
10	Interferon-α effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior. Molecular Psychiatry, 2010, 15, 535-547.	7.9	164
11	Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations. Brain, Behavior, and Immunity, 2013, 31, 153-160.	4.1	146
12	Depressive symptoms and viral clearance in patients receiving interferon- $\hat{l}\pm$ and ribavirin for hepatitis C. Brain, Behavior, and Immunity, 2005, 19, 23-27.	4.1	137
13	Paroxetine for prevention of depressive symptoms induced by interferonâ€alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics, 2007, 25, 1163-1174.	3.7	130
14	IFN-Alpha-Induced Cortical and Subcortical Glutamate Changes Assessed by Magnetic Resonance Spectroscopy. Neuropsychopharmacology, 2014, 39, 1777-1785.	5.4	130
15	Chronic Interferon-Alpha Administration Disrupts Sleep Continuity and Depth in Patients with Hepatitis C: Association with Fatigue, Motor Slowing, and Increased Evening Cortisol. Biological Psychiatry, 2010, 68, 942-949.	1.3	106
16	Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain, Behavior, and Immunity, 2016, 56, 281-288.	4.1	102
17	Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacology, 2020, 45, 998-1007.	5.4	101
18	Inflammation negatively correlates with amygdala-ventromedial prefrontal functional connectivity in association with anxiety in patients with depression: Preliminary results. Brain, Behavior, and Immunity, 2018, 73, 725-730.	4.1	81

#	Article	IF	CITATIONS
19	Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. Translational Psychiatry, 2018, 8, 189.	4.8	78
20	Double Jeopardy: Schizophrenia and Substance Use. American Journal of Drug and Alcohol Abuse, 2000, 26, 343-353.	2.1	73
21	Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain, Behavior, and Immunity, 2015, 47, 193-200.	4.1	59
22	Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain, Behavior, and Immunity, 2013, 31, 205-215.	4.1	57
23	Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings. Brain, Behavior, and Immunity, 2015, 46, 17-22.	4.1	56
24	Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue. Psychological Medicine, 2012, 42, 1591-1603.	4.5	53
25	Neurobehavioral Effects of Interferon-α in Patients with Hepatitis-C: Symptom Dimensions and Responsiveness to Paroxetine. Neuropsychopharmacology, 2012, 37, 1444-1454.	5.4	51
26	Increased Early Life Stress and Depressive Symptoms in Patients With Comorbid Substance Abuse and Schizophrenia. Schizophrenia Bulletin, 2002, 28, 223-231.	4.3	48
27	Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology, 2018, 98, 222-229.	2.7	44
28	Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia. Brain, Behavior, and Immunity, 2020, 88, 161-165.	4.1	42
29	Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain, Behavior, and Immunity, 2011, 25, 1094-1098.	4.1	38
30	Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. Physiology and Behavior, 2016, 166, 14-21.	2.1	38
31	Promoter Polymorphisms of the Interferon-α Receptor Gene and Development of Interferon-Induced Depressive Symptoms in Patients with Chronic Hepatitis C: Preliminary Findings. Neuropsychobiology, 2005, 52, 55-61.	1.9	32
32	Relationship of Clinical Symptoms and Substance Use in Schizophrenia Patients on Conventional Versus Atypical Antipsychotics. American Journal of Drug and Alcohol Abuse, 2003, 29, 553-566.	2.1	29
33	Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study. Journal of Psychiatric Research, 2006, 40, 669-676.	3.1	29
34	Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression. Brain, Behavior, and Immunity, 2020, 88, 193-202.	4.1	21
35	Transcriptomic signatures of psychomotor slowing in peripheral blood of depressed patients: evidence for immunometabolic reprogramming. Molecular Psychiatry, 2021, 26, 7384-7392.	7.9	15
36	Kynurenines increase MRS metabolites in basal ganglia and decrease resting-state connectivity in frontostriatal reward circuitry in depression. Translational Psychiatry, 2021, 11, 456.	4.8	8

#	Article	IF	CITATIONS
37	543 - Cultural Considerations for Older LGBTQ Adults During the COVID-19 Pandemic: Case and Review. International Psychogeriatrics, 2021, 33, 85-86.	1.0	0